Treasury Proposes Ban on US Investment in Chinese Biotech
Proposed COINS rules would bar US persons from investing in Chinese biotechnology firms developing small molecules, biologics and gene therapies.
Updated on Nov. 10, 2026 in Healthcare

The US Treasury Department has proposed regulations that would prohibit US persons from investing in Chinese biotechnology companies involved in developing or producing drugs, vaccines, and cell and gene therapies. Joint ventures with Chinese partners for such activities would also be banned.
Why it matters
The proposal extends US restrictions on foreign investment into the healthcare sector, carrying civil penalties of up to $250,000 or twice the transaction value. It also applies a 'knew or should have known' liability standard and covers evasive or obfuscated deal structures.
The proposed rules carry civil penalties of up to $250,000 or twice the transaction value, with a 30-day notification requirement for post-closing discovery of covered facts. Public comments close December 7, 2026, and the final rule is expected by mid-March 2027.
The players
US Treasury Department
The federal department responsible for managing government finances and administering economic sanctions and foreign investment restrictions, which proposed the COINS rules.
Department of Justice
The federal law enforcement department that designated its Fraud Division as the single point of contact for healthcare conduct disclosures and runs the healthcare False Claims Act pilot program.
HHS Office of Inspector General
The inspector general office within the US Department of Health and Human Services that oversees its Self-Disclosure Protocol, which DOJ disclosures now automatically reference.
The details
Under the proposed COINS rules, compelled divestment of prohibited investments is included, and liability extends to structures designed to evade the restrictions. Separately, the DOJ Fraud Division was designated the single point of contact for disclosing potential criminal healthcare conduct, and companies disclosing to DOJ automatically receive HHS-OIG Self-Disclosure Protocol benefits.
Timeline
October 2026: DOJ Civil Division and HHS launched a six-month Healthcare False Claims Act Self-Disclosure Pilot Program.
December 7, 2026: Public comment deadline for the proposed COINS rules.
April 22, 2027: The FCA self-disclosure pilot program closes.
Mid-March 2027: Final COINS rule expected.
Sector Expansion
The proposed rules extend the COINS framework's investment restrictions beyond prior targets into biotechnology, covering small molecules, biologics, vaccines and cell and gene therapies. The move signals that healthcare research and drug development now fall within the same national security investment scrutiny applied to other strategic industries.
US investors and firms with biotechnology holdings or partnerships in China could face compelled divestment and penalties if the rules take effect. Healthcare companies reviewing disclosure options should note that DOJ disclosures now automatically qualify for HHS-OIG Self-Disclosure Protocol benefits.
The takeaway
Companies with exposure to Chinese biotechnology should review holdings and joint ventures before the COINS rules are finalized. Healthcare providers and firms should also assess their disclosure strategy, since a single DOJ disclosure now carries HHS-OIG protections.
What happens next
Public comments on the proposed COINS rules close December 7, 2026, and the Treasury Department's final rule is expected by mid-March 2027. The DOJ and HHS False Claims Act self-disclosure pilot program closes April 22, 2027.
Further reading
For related coverage, explore Healthcare news on the sector's regulatory and enforcement environment.
Source note: This article includes information reported by BioXconomy.






